CWC
SRPT icon

Carolinas Wealth Consulting’s Sarepta Therapeutics SRPT Stock Holding History

Carolinas Wealth Consulting’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-90
Closed -$8K – 1003
2021
Q4 		$8K Hold
90
– – ﹤0.01% 651
2021
Q3 		$8K Hold
90
– – ﹤0.01% 615
2021
Q2 		$7K Hold
90
– – ﹤0.01% 664
2021
Q1 		$7K Hold
90
– – ﹤0.01% 667
2020
Q4 		$15K Buy
+90
New +$13.3K ﹤0.01% 525

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Carolinas Wealth Consulting's SRPT Position: Q1 2022 in Review

Carolinas Wealth Consulting sold out of Sarepta Therapeutics (SRPT) in Q1 2022, closing a stake of 90 shares — an estimated $8K sold.

Carolinas Wealth Consulting first reported a position in SRPT in Q4 2020 and held it in 5 quarters. The position peaked at $15K in Q4 2020. 328 funds tracked by Wall St. Rank hold SRPT as of Q1 2022.

  • Carolinas Wealth Consulting reported no remaining Sarepta Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Carolinas Wealth Consulting sold 90 Sarepta Therapeutics shares in Q1 2022, an estimated $8K.
  • Carolinas Wealth Consulting first reported a position in Sarepta Therapeutics in Q4 2020 and held it in 5 quarters.
  • Carolinas Wealth Consulting's Sarepta Therapeutics position peaked at $15K in Q4 2020.
  • 328 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2022.

Based on Carolinas Wealth Consulting's 13F filing for Q1 2022, filed 17 May 2022.